The 18th Frost & Sullivan China Growth, Innovation and Leadership Summit and the 3rd New Investment Conference - Life Sciences New Investment Summit Forum were held atThe forum will be held in Shanghai from August 28th to 29th, 2024. It brings together over 40 industry leaders, biopharmaceutical companies, medical device enterprises, investment institutions, and professional service providers. With the theme of "Responding to Changes and Opening up New Horizons," all participants will discuss new models of investment cooperation, aiming to build a closer, more efficient, and win-win cooperative network to jointly promote the vigorous development of the domestic and international life science industry.
At this forum, titledThe roundtable dialogue, themed 'Breaking the Vicious Cycle from 'Insider Competition' to 'Going Global', aimed to explore how to seize opportunities. The moderator for this roundtable was Liu Da, Managing Director of the China Resources Zhengda Life Science Fund. Guests included Dr. Qin Gang, Founder and Chairman of Qide Medicine; Cai Huiming, Chairman and President of Nuoyuan Medical; Chen Youchen, Vice President of Hebo Medicine and Head of Investor Relations and Corporate Development; and Xiao Jia, Director of the Life Sciences Industry at the Irish Investment Development Board.
Q
A
&
Managing Director of China Resources Cinda Life Sciences Fund Liuda
Liuda Please introduce yourself, your glorious past, and what you are currently doing.
Founder and Chairman of Qide Medicine Dr. Qin Gang
Dr. Qin Gang Qide Medicine was established inTen years ago, I actually came out of the ivory tower, focusing on the innovation and development of ADC (antibody-drug conjugates). As an enterprise transitioning from research to industry, Qide has built an end-to-end solution for ADC drugs. The company's R&D has entered a later stage, with one project having progressed to phase III clinical trials. Through innovation in underlying technologies, Qide has gradually achieved success in new drug R&D.
Chairman and President of Nuoyuan Medical Cai Huiming
Cai Huiming The Nuoyuan Medical startup team is mainly composed of researchers from China Pharmaceutical University and Nanjing University, focusing on molecular imaging technology. It represents a typical new model of concurrent development of pharmaceuticals and medical devices, as well as coordinated development between them. Nuoyuan Medical's core products involve the development of molecularly targeted diagnostic contrast agents and equipment, and has established multiple international collaborations. Nuoyuan is promoting the market entry of several innovative drug and device projects, including some globally first-in-class products.
VP Investor Relations and Corporate Development, Hepalink Chen Youchen
Chen Youchen Hippo Oncology is committed to the next generation of inflammation and immunity, including the development of innovative drugs for autoimmune diseases, especially having made breakthroughs in the research and development of antibody drugs. Hippo Oncology has established partnerships with several top global pharmaceutical companies (such as AstraZeneca, Pfizer, etc.) through its antibody technology platform. The company not only has laboratories and R&D teams in China but also in Europe and America, striving to promote drug innovation globally. I used to work in investment banking.I started focusing on the healthcare industry in 2017 and have also conducted many IPOs in Hong Kong and the US.
Director, Life Sciences at Invest Ireland Xiao Jia
Xiao Jia The Irish Investment Development Agency is an investment promotion agency of the Irish government, helping more enterprises set up operations or develop in Ireland. The life sciences sector is a pillar industry of Ireland, with many of the world's top pharmaceutical companies having operational centers in Ireland. I am personally responsible for the life sciences industry in China and have several successful cases of Chinese enterprises settling in Ireland.
Q
A
&
Liuda : fromHow can we seize opportunities in breaking the deadlock from 'involution' to 'going global'? Please share your thoughts based on your respective companies.
Dr. Qin Gang In recent years, especially in the field of innovative drugsADC drugs have gained widespread recognition in the global market. Qide Medicine's strategy for going global is based on the product's technological advantages and global layout. It has successfully promoted its ADC drugs to overseas markets through international cooperation. A major challenge faced by domestic innovative drug companies is the limitations of the domestic market payment system. However, through 'going global', companies can achieve rapid monetization and inject funds into continuous research and development. Through cooperation in the global market, Qide Medicine's drug research and development has entered a virtuous cycle. Going global still focuses on globalization, but in the current environment, we hope to innovate to address challenges such as regional drug commercialization and supply chain accessibility, thereby serving social needs.
Cai Huiming Nuoyuan Medical's experience in going global is concentrated in the field of drug-device integration. The company has adopted a strategy of collaborating with global leading enterprises during its internationalization process, especially through partnerships with German company Beren and Japanese company Shimadzu, to promote the globalization of its product portfolio. Going global is not only about selling products but also about enhancing one's own technical and market competitiveness through cooperation with top companies worldwide. Under the current economic situation, going global has become an inevitable choice for enterprises seeking international breakthroughs, but companies should flexibly respond to changes in the international market based on their own advantages and strategies. We are in the long-term development stage of precision medicine, and we must focus on meeting clinical needs and improving patient welfare. Only by actively participating in international competition can we enhance the value of innovative drugs and high-end medical devices. Although the current wave of going global is enthusiastic, companies need to remain calm, strengthen their internal capabilities, and achieve long-term success by reaching international advanced levels through differentiated competition.
Chen Youchen During its overseas expansion, Hebiopharm has placed particular emphasis on cooperation with global pharmaceutical giants. Hisbiopharm's technology platform enables it to compete in the international market and has successfully established deep collaborations with companies such as AstraZeneca and Pfizer. Through these collaborations, the company has not only made technological breakthroughs but alsoBD transactions have generated short-term cash flows. With the intensification of industry competition, data rigor and technological foresight have become key for companies to stand out in the global market. Facing the winter of the capital market, companies need to possess the ability to quickly adjust, make forward-looking arrangements based on changes in international situations, and seek new growth points.
Xiao Jia From the perspective of globalization trends, going global is not a passive choice in the short term, but an important strategy for global enterprises to expand their markets.The main reasons for accelerating 'going global' are, first and foremost, biosecurity issues, serving as a buffer for intellectual property rights. As Chinese innovative pharmaceutical companies gradually rise to prominence, more and more enterprises choose to set up R&D and production bases in Europe to plan for future sales. In the medical device industry, some companies aim to create high-end brands and prefer to enter the high-end market with the 'Made in Europe' brand. There are also companies that have already developed globally, with the purpose of improving overseas functional support, such as after-sales service and other service-oriented work. The prerequisite for going global is that the company's products or services must be competitive; enthusiasm and passion alone are not enough, as international market competition is more intense. Going global is a long-term process that requires dealing with information asymmetry and cultural differences; patience is more important than enthusiasm.
Liuda The growth of the industry cannot be separated from years of accumulation, and the value of this accumulation cannot be underestimated. The ultimate goal of life science technology is to serve the health of all humanity, and global cooperation is indispensable. The current environment is the most unfriendly era in recent decades, but it is believed that this situation will pass; when most people are pessimistic, it may mean that opportunities are about to arrive, and one must maintain learning and thinking during difficult times.
